Gilead Sciences
Logotype for Gilead Sciences Inc

Gilead Sciences (GILD) investor relations material

Gilead Sciences Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Gilead Sciences Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Business outlook

  • Q3 delivered the strongest growth in more than a decade, with contributions across HIV, oncology and inflammation; management expects strong top- and bottom-line growth ahead.

  • HIV growth, oncology expansion and inflammation investment are diversifying the portfolio; BIKTARVY’s 2036 patent expiry is identified as the only major patent cliff.

Inflammation strategy

  • Oral alpha-4-beta-7 phase II data were described as potentially matching IV or injectable efficacy with good tolerability; development will pursue monotherapy and combinations in UC and IBD.

  • Tolerability may support use in moderate and milder disease; an in-licensed potent IL-23 peptide has potential for once-monthly dosing and possible oral combinations or co-formulation.

  • Inflammation is positioned as a 2030 growth opportunity; gamgertamig, a BCMAxCD3 B-cell depleter, could be the first potential launch, potentially in the early 2030s.

Oncology and Tubulis

  • Tubulis’ lead NaPi2b ADC targets ovarian cancer, with potential in endometrial and lung cancers; 5T4 and additional payloads are also in development.

  • Management highlighted the tight linker’s potential to support combinations with chemotherapy or other agents, across ovarian cancer and other tumor types.

  • Management expressed confidence in the ovarian cancer dose and expects to share more data in 2027; external combination partnerships remain an option.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Gilead Sciences earnings date

Logotype for Gilead Sciences Inc
Citi Annual Global Healthcare Conference 20261 Dec, 2026
Gilead Sciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Gilead Sciences earnings date

Logotype for Gilead Sciences Inc
Citi Annual Global Healthcare Conference 20261 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company's products address chronic diseases such as hepatitis C virus infection; and the company participates in the product development partnerships with Bristol-Myers Squibb Company to develop HIV direct acting antiviral drugs based on discoveries made at the company's San Francisco research facility. The company was founded in 1987 and is headquartered in Foster City, California.